Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
No new safety signals were reported.On Wednesday, Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced a preplanned interim analysis of the Reliance II Phase 3 study.
在周三，relmada therapeutics公司（纳斯达克：RLMD）宣布了Reliance II III期研究的预先计划中期分析。
Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants.
Reliance II的设计目的是评估REL-1017作为主要抑郁障碍（MDD）的辅助治疗，与其他已批准的抗抑郁药物联用。
The Independent Data Monitoring Committee (DMC) analysis indicated that the Reliance II Phase 3 study is futile and unlikely to meet the primary efficacy endpoint with statistical significance.
独立数据监测委员会（DMC）的分析表明，Reliance II III期研究无效，不太可能以统计显著性达到主要疗效终点。
No new safety signals were reported.
没有报告新的安全信号。
"We are disappointed with the outcome of this interim analysis," said Sergio Traversa, Chief Executive Officer of Relmada. "Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program. The Company will continue to advance the Phase 1 study of REL-P11, an investigational agent for the treatment of metabolic disease, currently in a Phase 1 first-in-human study. We are grateful to the investigative sites and patients who participated in the REL-1017 program."
“我们对这次中期分析的结果感到失望，”relmada的首席执行官Sergio Traversa说。“基于这些结果，relmada将评估完整的数据集以判断REL-1017项目的下一步。该公司将继续推进REL-P11的I期研究，这是一种用于治疗代谢疾病的研究药物，目前正在进行I期首次人体试验。我们对参与REL-1017项目的研究站点和患者表示感谢。”
In July 2021, Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program. Psilocybin has neuroplastogen effects that have the potential to ameliorate neurodegenerative conditions.
在2021年7月，relmada获得了一项新型迷幻蘑菇及其衍生物项目的开发和商业权利。迷幻蘑菇具有神经可塑作用，可能改善神经退行性疾病。
Relmada identified the potential to use low-dose psilocybin to treat metabolic diseases and published the data at the American Society for the Study of Liver Disease.
relmada发现可以使用低剂量的迷幻蘑菇治疗代谢疾病，并在美国肝病研究学会发布了相关数据。
Last year, Relmada Therapeutics released efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
去年，relmada therapeutics公布了REL-1017在主要抑郁障碍（MDD）患者中进行的III期试验（310号研究）新治疗患者（204名患者）的疗效结果和所有受试者（627名患者）的安全性结果。
Patients treated daily with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment.
接受了每日REL-1017治疗最多一年的患者，迅速、明显且持续改善了抑郁症状和相关功能障碍。
In November, Relmada Therapeutics initiated dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. Phase 2a proof-of-concept study is expected to begin in the first half of 2025.
在11月份，relmada therapeutics启动了对REL-P11的第一阶段SAD研究，该药物是一种用于代谢疾病的实验性药物。第二阶段的概念板块研究预计将在2025年上半年开始。
Price Action: RLMD stock is down 75.4% at $0.68 at last check Wednesday.
价格动向：RLMD股票在周三最后一次检查时下跌了75.4%，现价为$0.68。
- Edwards Lifesciences Outlines Vision For Growth At Investor Conference
- 爱德华生命科学在投资者会议上勾画了增长愿景。
Photo via Shutterstock
图片来自shutterstock
